166 related articles for article (PubMed ID: 8797480)
1. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.
Inzelberg R; Nisipeanu P; Rabey JM; Orlov E; Catz T; Kippervasser S; Schechtman E; Korczyn AD
Neurology; 1996 Sep; 47(3):785-8. PubMed ID: 8797480
[TBL] [Abstract][Full Text] [Related]
2. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with cabergoline in patients with advanced Parkinson's disease treated with levodopa.
Marsden CD
Drugs; 1998; 55 Suppl 1():17-22. PubMed ID: 9483166
[TBL] [Abstract][Full Text] [Related]
4. Cabergoline versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke CE; Deane KD
Cochrane Database Syst Rev; 2001; 2001(1):CD001519. PubMed ID: 11279721
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off.
Deuschl G; Vaitkus A; Fox GC; Roscher T; Schremmer D; Gordin A;
Mov Disord; 2007 Aug; 22(11):1550-5. PubMed ID: 17516484
[TBL] [Abstract][Full Text] [Related]
6. Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group.
Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD
Drugs; 1998; 55 Suppl 1():23-30. PubMed ID: 9483167
[TBL] [Abstract][Full Text] [Related]
7. Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.
Ahlskog JE; Wright KF; Muenter MD; Adler CH
Clin Neuropharmacol; 1996 Jun; 19(3):202-12. PubMed ID: 8726539
[TBL] [Abstract][Full Text] [Related]
8. Cabergoline in Parkinson's disease: long-term follow-up.
Lera G; Vaamonde J; Rodriguez M; Obeso JA
Neurology; 1993 Dec; 43(12):2587-90. PubMed ID: 7902970
[TBL] [Abstract][Full Text] [Related]
9. A six-month multicentre, double-blind, bromocriptine-controlled study of the safety and efficacy of ropinirole in the treatment of patients with Parkinson's disease not optimally controlled by L-dopa.
Brunt ER; Brooks DJ; Korczyn AD; Montastruc JL; Stocchi F;
J Neural Transm (Vienna); 2002 Apr; 109(4):489-502. PubMed ID: 11956968
[TBL] [Abstract][Full Text] [Related]
10. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
Del Dotto P; Colzi A; Pardini C; Lucetti C; Dubini A; Grimaldi R; Bonuccelli U
J Neural Transm Suppl; 1995; 45():259-65. PubMed ID: 8748633
[TBL] [Abstract][Full Text] [Related]
11. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
Linazasoro G;
Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
[TBL] [Abstract][Full Text] [Related]
12. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group.
Rinne UK; Bracco F; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; Marsden CD; Dubini A; Orlando N; Grimaldi R
Neurology; 1997 Feb; 48(2):363-8. PubMed ID: 9040722
[TBL] [Abstract][Full Text] [Related]
13. Use of the dopamine agonist cabergoline in the treatment of movement disorders.
Marco AD; Appiah-Kubi LS; Chaudhuri KR
Expert Opin Pharmacother; 2002 Oct; 3(10):1481-7. PubMed ID: 12387694
[TBL] [Abstract][Full Text] [Related]
14. Early combination of bromocriptine and levodopa in Parkinson's disease: a prospective randomized study of two parallel groups over a total follow-up period of 44 months including an initial 8-month double-blind stage.
Giménez-Roldán S; Tolosa E; Burguera JA; Chacón J; Liaño H; Forcadell F
Clin Neuropharmacol; 1997 Feb; 20(1):67-76. PubMed ID: 9037575
[TBL] [Abstract][Full Text] [Related]
15. Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline.
Ahlskog JE; Muenter MD; Maraganore DM; Matsumoto JY; Lieberman A; Wright KF; Wheeler K
Arch Neurol; 1994 Dec; 51(12):1236-41. PubMed ID: 7986180
[TBL] [Abstract][Full Text] [Related]
16. Beneficial effect of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease.
Rabey JM; Nissipeanu P; Inzelberg R; Korczyn AD
Clin Neuropharmacol; 1994 Jun; 17(3):286-93. PubMed ID: 9316674
[TBL] [Abstract][Full Text] [Related]
17. Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease.
Inzelberg R; Nisipeanu P; Rabey MJ; Korczyn AD
Mov Disord; 1995 Sep; 10(5):604-7. PubMed ID: 8552112
[TBL] [Abstract][Full Text] [Related]
18. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
Im JH; Ha JH; Cho IS; Lee MC
J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
[TBL] [Abstract][Full Text] [Related]
19. Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.
Lieberman A; Imke S; Muenter M; Wheeler K; Ahlskog JE; Matsumoto JY; Maraganore DM; Wright KF; Schoenfelder J
Neurology; 1993 Oct; 43(10):1981-4. PubMed ID: 8105422
[TBL] [Abstract][Full Text] [Related]
20. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
